When time is precious

Initiating Drogenil for metastatic cancer patients could optimise not only time to progression and survival time but also the quality of that life.1-6

As monotherapy, Drogenil is comparable to castration in terms of survival time,7 and unlike castration, Drogenil patients can keep their libido and potency,5,5 helping them to sustain a loving relationship. Drogenil is the only non-steroidal anti-androgen recommended for monotherapy.

As part of combination therapy in maximal androgen blockade (MAB), of all the anti-androgens, including the recently launched bicalutamide, only Drogenil has proven survival advantage over orchidectomy or medical castration1,2 – offering patients the chance of more precious time.

FOR LIVING WITH PROSTATE CANCER
FORTHCOMING PAPERS IN THE
BRITISH JOURNAL OF CANCER

Experimental Oncology
Selective uptake of boronated low density lipoprotein in melanoma xenografts achieved by diet supplementation
Y Setiawan, DE Moore and BJ Allen

Combined effect of clinically relevant doses of emitefur, a new 5-fluorouracil derivative, and radiation in murine tumours
Y Shibamoto, R Murata, S Miyaochi, M Hirohashi, T Takagi, K Sasai, T Shibata, N Oya and M Takahashi

In vivo pharmacology and anti-tumour evaluation of the tyrophostin tyrosine kinase inhibitor RG13022
HL McLeod, VG Brunton, N Eckardt, MJ Lear, DJ Robins, P Workman and MA Graham

Human hepatoma cells rich in P-glycoprotein are sensitive to aclacinomycin and resistant to three other anthracyclines
G Lehne, P De Angelis, OPF Clausen, and HE Rugstad

Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours
JM Sargent, AW Elgie, CJ Williamson and CG Taylor

Intrinsic radiosensitivity of human pancreatic tumour cells and the radiosensitising potency of the bioreductive nitric oxide donors sodium nitroprusside
VN Veroskij, DL Van den Berge, GA Soete, B Bols and GA Storme

What is an apoptotic index measuring?
CS Potten

Targeting of stealth liposomes to erb-B-2 (Her2) receptor: in vitro and in vivo studies
D Goren, AT Horowitz, Z Zalitksy, MC Woodle, Y Yarden and A Gabizon

Epithelial ovarian cancer: influence of polymorphism at the glutathione S-transferase GSTM1 and GSTT1 loci on p53 expression
P Sarhanis, CWE Redman, C Perrett, K Branigan, RN Clayton, P Hand, C Muagrove, V Suarez, PW Jones, AA Fryer, WE Farrell and RC Strange

Beta-1 integrins mediate tumour cell adhesion to quiescent endothelial cells
EA Price, DR Coombe and JC Murray

Mechanism of PAP I gene induction during hepatocarcinogenesis: clinical implications
NJ Dusetti, G Montalvo, EM Ortiz, L Masciotta, J-C Dagorn and JL Lovanna

Interphase cytogenetics of prostate cancer: fluorescence in situ hybridization (FISH) analysis of Japanese cases
H Matsuura, T Shiraiishi, R Yatani and J Kawamura

An enhanced and sensitive autocrine stimulation by transforming growth factor α is acquired in the brain metastatic variant of a human non-small cell lung cancer cell line
K Fang

Expression of oncoproteins and the amount of eosinophilic and lymphocytic infiltrates can be used as prognostic factors in gastric cancer
I Songun, CJH van der Velde, J Hermans, ST Pals, HW Verspaget, AN Vis, AG Menon, SV Litvinov and HJBM van Krieiken

Extraclonal features of familial adenomatous polyposis in patients with sporadic colorectal cancer
MG Dunlop, SM Farrington, VJ Bubb, C Cunningham, M Wright, LJ Curtis, ZA Butt, E Wright, BW Fleck, D Redhead, R Mitchell, JB Rainey, IMC Macintyre, DC Carter and AH Wylie

Breast carcinomas occurring in young women (>35 years) are different
RA Walker, E Lees, M Webb and SJ Dearing

Variability of mm23-H1/NDPK-A expression in human lymphomas and its relation to tumour aggressiveness
DNT Aryee, I Simonitsch, I Moserberger, K Kos, G Mann, A Schlogl, U Potschger, H Gneden, T Radaszkiewics and H Kovar

MHC class I antigens and tumour-infiltrating leukocytes in laryngeal cancer: long-term follow-up
F Esteban, M Redondo, M Delgado, F Garrido and F Ruiz-Cabello

Clinical Oncology
Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer. A multicentre randomized trial
P Comella, G Frasci, G de Cataldis, N Panza, R Cioffi, C Curcio, M Belli, A Bianco, G Iannelli, L Maiorino, MD Vittoria, J Perchard and G Comella

Survival of classic Karposi's sarcoma and risk of second cancer
S Franceschi, S Arriani, D Balzi and M Geddes

The use of 99mTc-MIBI scanning in multiple myeloma
EB Tirolova, L Biassoni, KE Britton, N Kaleva, V Kouvkin and JS Malpas

A study of ovarian cancer patients treated with dose intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide
A Weaver, E Wrigley, A Watson, J Chang, CD Collins, B Jenkins, C Gill, R Pettengell, TM Dexter, NG Testa and D Crowther

Characterisation of immune responses in pancreatic carcinoma patients after mutar p21 ras peptide vaccination
MK Gjertsen, I Suctoral, E Thorsby and G Gauernack

Superficial spreading type of early gastric cancer
K Kitamura, T Yamaguchi, K Okamoto, T Takahashi and T Nishida

Mammographic screening after the age of 65 years: early and late outcomes in the Nijmegen programme
JAAM van Dijck, ALM Verbeek, JHCL Hendriks, R Holland and M Mravanac

Reproductive factors and prognosis of uterine cervical cancer in Norway
T Bjorge and Ø Kleveland

Non-Hodgkin's lymphomas, chronic lymphocytic leukaemias and skin cancers
F Levi, L Randimbison, V-C Te and C La Vecchia

Menstrual phase and timing of breast cancer surgery: statistical aspects
G Haasler, C Tempfer, C Kainz and H Heinl